Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (2): 101-105.DOI: 10.3969/j.issn.1673-8640.2018.02.002

• Orginal Article • Previous Articles     Next Articles

Anti-neutrophil cytoplasmic antibody determination for systemic vasculitis

TAN Liming1, JIAO Anjun2, FENG Xiaojing2, XU Liuyue2, TAN Fuyan2, HE Siqi2, LUO Heng1, CHEN Juanjuan1, JIANG Yongqing1, LI Hua1   

  1. 1. Department of Clinical Laboratory,the Second Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi,China
    2. School of Public Health,Nanchang University,Nanchang 330031,Jiangxi,China;
  • Received:2017-04-28 Online:2018-02-28 Published:2018-03-02

Abstract:

Objective To evaluate the role of anti-neutrophil cytoplasmic antibody(ANCA) determination for systemic vasculitis. Methods Indirect immunofluorescence(IIF) was performed to determine serum ANCA in 13 866 patients,and enzyme-linked immunosorbent assay(ELISA) was used to determine anti-myeloperoxidase(MPO) antibody and anti-protease 3(PR3) antibody. Results Among the 13 866 patients,there were 318 positive cases of ANCA,with the positive rate of 2.29%. There were 135(2.07%) males and 183(2.50%) females,and there was no statistical significance between the 2 groups(χ2=2.650,P>0.05). The difference of the ANCA positive rate with different ages had statistical significance(χ2=28.978,P<0.01). The positive rate of ANCA between males and females in different age groups had statistical significance(χ2=54.550,P<0.01;χ2=17.800,P<0.01). The p-ANCA and c-ANCA and target antigen distribution had statistical significance(χ2=86.524,P<0.01). Conclusions ANCA is potential in the diagnosis and treatment of vasculitis and autoimmune diseases,especially for ANCA-associated systemic vasculitis.

Key words: Anti-neutrophil cytoplasmic antibody, Anti-myeloperoxidase antibody, Anti-protease 3 antibody, Wegener's granulomatosis, Systemic lupus erythematosus

CLC Number: